These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16494584)

  • 41. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials.
    Cheng SJ; Bonis PA; Lau J; Pham NQ; Wong JB
    Hepatology; 2001 Jan; 33(1):231-40. PubMed ID: 11124841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A; Selim O; Haddad S; Simmonds P; Hamdy H; Badran HM; Shawky S
    Ital J Gastroenterol Hepatol; 1999; 31(6):472-5. PubMed ID: 10575565
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucocorticosteroids for viral hepatitis C.
    Brok J; Mellerup MT; Krogsgaard K; Gluud C
    Cochrane Database Syst Rev; 2004; 2004(2):CD002904. PubMed ID: 15106184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment of chronic hepatitis C: a systematic review and meta-analysis of randomized clinical trials].
    Qin XK; Han M; Liu JP
    Zhong Xi Yi Jie He Xue Bao; 2009 Oct; 7(10):913-28. PubMed ID: 19828101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.
    Chang CH; Chen KY; Lai MY; Chan KA
    Aliment Pharmacol Ther; 2002 Sep; 16(9):1623-32. PubMed ID: 12197841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients.
    Fabrizi F; Lunghi G; Dixit V; Martin P
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1413-22. PubMed ID: 17081162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review.
    Tamborini Permunian E; Gervaso L; Gerdes V; Moja L; Guasti L; Squizzato A
    Intern Emerg Med; 2018 Aug; 13(5):775-790. PubMed ID: 29611106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Success in treating mild chronic hepatitis C: different outcomes -- new guidelines?
    Rosenberg WM
    Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):595-7. PubMed ID: 12072592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
    Flamm S; Lawitz E; Borg B; Charlton M; Landis C; Reddy KR; Shiffman M; Alsina A; Chang C; Ravendhran N; Hernandez C; Hézode C; Scherbakovsky S; Mercier RC; Samuel D
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination.
    Lindblom N; Lindquist L; Westman J; Åström M; Bullock R; Hendrix S; Wahlund LO
    J Alzheimers Dis Rep; 2021 May; 5(1):413-431. PubMed ID: 34189413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.
    Abraha I; Cherubini A; Cozzolino F; De Florio R; Luchetta ML; Rimland JM; Folletti I; Marchesi M; Germani A; Orso M; Eusebi P; Montedori A
    BMJ; 2015 May; 350():h2445. PubMed ID: 26016488
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.
    Kim JS; Ahn SM; Jung YK; Kwon OS; Kim YS; Choi DJ; Kim JH
    J Korean Med Sci; 2013 Aug; 28(8):1213-9. PubMed ID: 23960450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The application and mechanism of action of ribavirin in therapy of hepatitis C.
    Thomas E; Ghany MG; Liang TJ
    Antivir Chem Chemother; 2012 Sep; 23(1):1-12. PubMed ID: 22592135
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.
    Thomas E; Feld JJ; Li Q; Hu Z; Fried MW; Liang TJ
    Hepatology; 2011 Jan; 53(1):32-41. PubMed ID: 21254160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy.
    Lin E; Hwang Y
    Mol Diagn Ther; 2008; 12(4):219-23. PubMed ID: 18652518
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful rescue therapy with only 4 weeks ribavirin monotherapy in end-stage cirrhosis due to genotype 2 chronic hepatitis C.
    Howaizi M; Akue-Goeh P; Maurer-Chagrin F
    Dig Dis Sci; 2009 Feb; 54(2):409-10. PubMed ID: 18548349
    [No Abstract]   [Full Text] [Related]  

  • 60. Nonresponse to treatment for hepatitis C: current management strategies.
    Yuan HJ; Lee WM
    Drugs; 2008; 68(1):27-42. PubMed ID: 18081371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.